Coverage window: June 12-July 24, 2026
The last six weeks were unusually clinical. ISSCR 2026 put several neural replacement programs in front of the field at once, while trial records added new details on Parkinson's disease, Huntington's disease, spinal cord injury, chronic stroke, retinitis pigmentosa, neonatal hypoxic-ischemic encephalopathy, Alzheimer's disease, and multiple system atrophy.
That makes this issue less about a single breakthrough and more about how the field is taking shape: direct CNS delivery, sham controls, long follow-up, retinal imaging, immunosuppression, and much more specific trial endpoints.
1. Parkinson's cell-replacement programs had a crowded July
Primary sources:
- https://www.isscr.org/isscr-news/new-clinical-data-presented-at-isscr-2026-advance-stem-cell-based-cell-therapy-for-parkinsons-disease
- https://www.kenaitx.com/press-release-7-7-26
- https://clinicaltrials.gov/study/NCT06944522
Three Parkinson's cell-replacement updates landed close together.
At ISSCR 2026, investigators presented 12-month findings from STEM-PD, a Phase I/II trial of a cryopreserved, off-the-shelf human pluripotent stem-cell-derived dopaminergic progenitor product. The presentation focused on safety, feasibility, and biological activity after transplantation in people with moderately advanced Parkinson's disease.
Kenai Therapeutics announced that it completed enrollment in REPLACE, its 12-participant Phase 1b/2a trial of RNDP-001, an off-the-shelf allogeneic neuron replacement product for idiopathic Parkinson's disease. And BlueRock's bemdaneprocel Phase 3 record remains one of the most important active comparators in the space: ClinicalTrials.gov lists a randomized, sham surgery-controlled study with 102 estimated participants.
Why it matters: Parkinson's disease is no longer represented by one cell-replacement bet. The field now has multiple dopaminergic progenitor programs moving through human studies at different levels of maturity, from open-label early studies to a sham-controlled Phase 3 trial.
Full analysis: Parkinson Cell Replacement Is Becoming a Field, Not a Single Story
2. Huntington's disease gets its first pluripotent neural stem-cell trial
Primary sources:
- https://www.isscr.org/isscr-news/first-clinical-trial-of-pluripotent-stem-cell-derived-neural-stem-cells-for-huntingtons-disease-highlighted-at-isscr-2026
- https://clinicaltrials.gov/study/NCT07451613
ISSCR highlighted REGEN4HD, described as the first clinical trial of a pluripotent stem-cell-derived neural stem-cell product for Huntington's disease. The study is enrolling relatively early-stage symptomatic adults and begins with a Phase 1b dose-escalation component before moving into a Phase 2a dose-finding stage.
The ClinicalTrials.gov record lists hNSC-01, 21 estimated participants, sequential assignment, no masking, and treatment-related adverse events as the primary early safety measure.
Why it matters: Huntington's disease is a hard test for regenerative medicine because the disease is diffuse, progressive, and slow enough that early outcome interpretation is difficult. A first human trial does not settle the therapeutic question, but it does move the program from preclinical rationale into a human safety-and-dose framework.
3. A first-in-human iPSC spinal cord injury trial now has 2-4 years of follow-up
Primary source: https://www.nature.com/articles/s41591-026-04549-6
Nature Medicine published an open-access Phase 1 study of iPSC-derived neural stem/progenitor cell transplantation in four patients with subacute cervical complete spinal cord injury.
The study used intramedullary delivery of 2 million iPSC-derived neural stem/progenitor cells into the injury site, with tacrolimus started around surgery, continued for six months, and tapered off by month nine. During 2-4 years of follow-up, the authors report no tumor formation and no graft-related adverse events. Exploratory motor and AIS-grade changes were encouraging in several participants, but the paper is appropriately careful: four patients and an open-label design cannot establish how much of the recovery came from the intervention.
Why it matters: this is a rare human data point for iPSC-derived neural cells placed directly into the spinal cord with multi-year follow-up. The encouraging part is that the treatment was manufactured, delivered, and followed for years without reported graft-related safety problems; the next stage needs controlled evidence strong enough to separate treatment effect from the variable natural history of spinal cord injury recovery.
Full analysis: A Four-Patient iPSC Spinal Cord Injury Trial Clears an Important First Test
4. Chronic stroke is moving toward harder trial designs
Primary sources:
- https://www.isscr.org/isscr-news/long-term-clinical-data-advance-stem-cell-research-for-chronic-stroke-recovery-presented-today-at-isscr-2026-in-montral-canada
- https://clinicaltrials.gov/study/NCT07709845
At ISSCR 2026, Hopstem presented long-term clinical and imaging follow-up from Phase I studies of hNPC01, an iPSC-derived forebrain neural progenitor product for chronic ischemic stroke.
A separate ClinicalTrials.gov record, posted on July 17, shows where this area may be heading. Clarion Cells' CC-101 study is listed as a not-yet-recruiting Phase 2 trial in adults with chronic ischemic stroke. The planned study has 36 estimated participants, randomized parallel assignment, quadruple masking, tacrolimus, a sham surgical control, and a Day 365 Fugl-Meyer motor score primary outcome.
Why it matters: chronic stroke is vulnerable to noisy interpretation because recovery, rehabilitation, baseline disability, and expectation can all shape outcomes. A year-long motor endpoint with a sham surgical control is the kind of design the field needs if neural cell transplantation is going to be judged clearly.
Full analysis: Chronic Stroke Cell Therapy Moves Toward the Trial Design It Needs
5. Retinal cell therapy keeps producing unusually visible human follow-up
Primary sources:
- https://www.isscr.org/isscr-news/new-clinical-data-presented-at-isscr-2026-demonstrate-one-year-survival-of-stem-cell-derived-neural-progenitor-cells-in-patients-with-retinitis-pigmentosa
- https://clinicaltrials.gov/study/NCT04284293
- https://clinicaltrials.gov/study/NCT06789445
ISSCR reported one-year clinical data from CNS10-NPC, a human neural progenitor cell product tested by subretinal injection in retinitis pigmentosa. The Phase 1/2a study followed 13 participants who received either 300,000 or 1,000,000 cells. Visual acuity remained stable during the first year, OCT imaging showed transplanted cells still present in the subretinal space, and reported cell-related adverse events included three epiretinal membranes and one persistent subretinal bleb.
The broader retinal replacement space is also active. BlueRock's OpCT-001 CLARICO record is recruiting adults with primary photoreceptor diseases, including retinitis pigmentosa, Usher syndrome, and inherited retinal degeneration, with treatment-emergent adverse events through week 52 as the primary safety measure.
Why it matters: retina remains one of the clearest places to learn how cell products behave in humans. Investigators can image anatomy, localize the graft site, follow structural change over time, and connect those observations to vision measures more directly than they can in most CNS targets.
6. A neonatal HIE trial pairs Wharton's jelly MSCs with cooling therapy
Primary source: https://clinicaltrials.gov/study/NCT07018739
Mahidol University updated a not-yet-recruiting Phase 1/2 study of Wharton's jelly-derived mesenchymal stem cells in infants with neonatal hypoxic-ischemic encephalopathy.
The trial record lists 40 estimated participants, randomized parallel assignment, quadruple masking, normal saline placebo, and death or neurological disability as the primary outcome. The design places MSCs alongside cooling therapy rather than as a standalone intervention.
Why it matters: neonatal HIE is a high-stakes neurologic setting where timing, baseline severity, and standard care already matter enormously. A masked placebo-controlled design is a useful way to test whether MSCs add anything measurable beyond therapeutic hypothermia and intensive neonatal care.
7. MSC trials in Alzheimer's disease and MSA show why the acronym is not enough
Primary sources:
Two updated CNS-adjacent MSC records are worth separating rather than lumping together.
University Hospital Toulouse is recruiting a small Phase 1/2 Alzheimer's disease study of CellREADY, an IV allogeneic adipose tissue-derived stem-cell product, with nine estimated participants and treatment-related adverse events as the main safety question. Mayo Clinic's multiple system atrophy study is further along operationally: the updated record lists 71 actual participants in a randomized, double-blind, placebo-controlled Phase 2 study of intrathecally administered autologous mesenchymal stem cells, with change in UMSARS total score as the primary outcome.
Why it matters: "MSC therapy" is not one thing. Source tissue, autologous versus allogeneic use, IV versus intrathecal delivery, disease biology, scale, comparator, and endpoint all change how a study should be read.